

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorial

- 161** Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
J E Pope, R M Fleischmann

Viewpoint

- 164** Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities
A Berti, F Atzeni, L Dagna, S Del Giacco, G Emmi, C Salvarani, A Vaglio

Review

- 169** Clinical trials in systemic lupus erythematosus: the dilemma—Why have phase III trials failed to confirm the promising results of phase II trials?
A Lorenzo-Vizcaya, D A Isenberg

Rheumatoid arthritis

- 175** After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries
M Pombo-Suarez, C Sanchez-Piedra, J Gómez-Reino, K Lauper, D Mongin, F Iannone, K Pavelka, D C Nordström, N Inanc, C Codreanu, K L Hyrich, D Choquette, A Strangfeld, B F Leeb, Z Rotar, A Rodrigues, E K Kristianslund, T K Kvien, O Elkayam, G Lukina, S A Bergstra, A Finckh, D S Courvoisier

- 182** Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
L Hoisnard, L Pina Vegas, R Dray-Spira, A Weill, M Zureik, E Sbidian

- 189** Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
V Molander, H Bower, T Frisell, B Delcoigne, D Di Giuseppe, J Asking, The ARTIS study group

- 198** PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes
J Tu, W Chen, Y Fang, D Han, Y Chen, H Jiang, X Tan, Z Xu, X Wu, H Wang, X Zhu, W Hong, Z Li, C Zhu, X Wang, W Wei

Spondyloarthritis

- 212** Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
R B M Landewé, D Poddubnyy, P Rahman, F E Van den Bosch, R Bolce, S Liu Leage, J R Lisse, S Y Park, L Gensler

Systemic lupus erythematosus

- 217** Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
M Petri, H Landy, M E B Clowse, K Gemzoe, M Khamashta, M Kurtinecz, R A Levy, A Liu, R Marino, P Meizlik, J M Pimenta, K Sumner, H Tilson, M B Connolly, K Wurst, J Harris, H Quasny, P Juliao, D A Roth

- 226** 3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
M Zhao, D Feng, L Hu, L Liu, J Wu, Z Hu, H Long, Q Kuang, L Ouyang, Q Lu

Myositis

- 235** Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies
D Zhou, E H King, S Rothwell, O Krystufkova, A Notarnicola, S Coss, R Abdul-Aziz, K E Miller, A Dang, G R Yu, J Drew, E Lundström, L M Pachman, G Mamyrova, R V Curiel, B De Paepe, J L De Bleecker, A Payton, W Ollier, T P O'Hanlon, I N Targoff, W A Flegel, V Sivaraman, E Oberle, S Akoghlianian, K Driest, C H Spencer, Y L Wu, H N Nagaraja, S P Ardoin, H Chinoy, L G Rider, F W Miller, I E Lundberg, L Padyukov, J Vencovský, J A Lamb, C-Y Yu, for MYOGEN Investigators

MORE CONTENTS ►Member since 2008
J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics
<http://publicationethics.org/>



When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.
See <http://authors.bmj.com/open-access/>

- 246** Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1 γ autoantibodies

Y Hosono, B Sie, I Pinal-Fernandez, K Pak, C A Mecoli, M Casal-Dominguez, B M Warner, M J Kaplan, J Albayda, S Danoff, T E Lloyd, J J Paik, E Tiniakou, R Aggarwal, C V Oddis, S Moghadam-Kia, C Carmona-Rivera, J C Milisenda, J M Grau-Junyent, A Selva-O'Callaghan, L Christopher-Stine, H B Larman, A L Mammen

Vasculitis

- 253** Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission

G Gamerith, F Mildner, P A Merkel, K Harris, L Cooney, N Lim, R Spiera, P Seo, C A Langford, G S Hoffman, E W St Clair, F C Fervenza, P Monach, S R Ytterberg, D Geetha, A Amann, D Wolf, U Specks, J H Stone, A Kronbichler

Osteoarthritis

- 262** Targeting FoxO transcription factors with HDAC inhibitors for the treatment of osteoarthritis

H Ohzono, Y Hu, K Nagira, H Kanaya, N Okubo, M Olmer, M Gotoh, I Kurakazu, Y Akasaki, M Kawata, E Chen, A C Chu, K A Johnson, M K Lotz

- 272** Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis

A J Knights, E C Farrell, O M Ellis, L Lammlin, L M Junginger, P M Rzeczycki, R F Bergman, R Pervez, M Cruz, E Knight, D Farmer, A A Samani, C-L Wu, K D Hankenson, T Maerz

Epidemiology

- 283** Understanding sex-related differences in healthcare utilisation among patients with inflammatory arthritis: a population-based study



S Tarannum, J Widdifield, C F Wu, S R Johnson, P Rochon, L Eder

- 292** Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls

F Kartnig, D Mrak, E Simader, S Tobudic, H Radner, P Mandl, L Göschl, N Hommer, M Mayer, P Hofer, T Hummel, T Deimel, I Geßl, A Puchner, A Kerschbaumer, R Thalhammer, A Handisurya, R Kain, S Winkler, J S Smolen, K Stiasny, T Perkmann, H Haslacher, J H Aberle, D Aletaha, L X Heinz, D Sieghart, M Bonelli

Images in rheumatology

- 302** Tumorous calcinosis of the atlantoaxial joint: the helmeted dens syndrome

F Verhoeven, M Chouk, C Delcourt, C Prati, D Wendling

Electronic pages

- e28** Correspondence on 'prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'

J Shi, Y Gao, L Zhang, Y Zhao, J Xu, J Tian

- e29** Response to 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Shi *et al*

S Akiyama, S Hamdeh, D Micic, A Sakuraba

- e30** Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey'

C Comarmond, M Leclercq, G Leroux, C Marques, A Le Joncour, F Domont, C Hatte, S Toquet-Bouedec, P Guillaume-Jugnot, A-C Desbois, M Vautier, A Rigolet, Y Allenbach, O Benveniste, D Saadoun, P Cacoub

- e31** Response to: 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey' by Comarmond *et al*

A Tomelleri, S Santorelli, E M Baldissera, L Dagna, C Campochiaro

- e32** Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort'

A Ruyssen-Witrand, M Soubrier, A Basch, M-E Truchetet, R Seror

- e33** Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand *et al*

A Ciurea, A Finckh

- e34** Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'

E Calvo-Aranda, I Cañamares-Orbis, M Novella-Navarro, A Martinez-Alcala, M d C Ortega de la O, I Escobar-Rodriguez, F M Sanchez-Aranda

- e35** Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda *et al*
S Ramiro, R Mostard, R BM Landewé
- e36** Correspondence on 'Systemic sclerosis and the COVID-19 pandemic—World Scleroderma Foundation preliminary advice for patient management'
E Snarskaya, K Vasileva
- e37** Response to: 'Correspondence on 'Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management'' by Snarskaya and Vasileva
C Bruni, M Matucci-Cerinic
- e38** Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD
M Benucci, A Damiani, G Giannasi, F Li Gobbi, L Quartuccio, V Grossi, M Infantino, M Manfredi
- e39** Impact of lockdown on rheumatology outpatient care in the age of COVID-19
B Sachdev Manjit Singh, S L Chuah, Y K Cheong, S A Wan, C L Teh
- e40** Correspondence on 'EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups'
I Mohammad, P K Devarasetti, L Rajasekhar
- e41** Response to: 'Correspondence on 'EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups'' by Irfan *et al*
I E Lundberg, F W Miller, L G Rider, V P Werth, A Tjärnlund, M Bottai
- e42** Correspondence on 'Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia'
G Evangelatos, G E Fragoulis, A Iliopoulos
- e43** Response to: 'Correspondence on 'Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia'' by Evangelatos *et al*
K SM van der Geest, B Dasgupta
- e44** Correspondence on 'EULAR recommendations for a core data set for pregnancy registries in rheumatology'
D De Cock, I Soenen, D Bertrand, S Pazmino, V Stouten, R Westhovens, P Verschueren
- e45** Response to: 'Correspondence on 'EULAR recommendations for a core data set for pregnancy registries in rheumatology'' by De Cock *et al*
Y Meissner, R Fischer-Betz, A Zinke, A Strangfeld
- e46** Correspondence on 'Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017'
P-H Chiang, P-C Ju, Y-C Chiang, J C-C Wei
- e47** Response to: 'Correspondence on 'Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the Global Burden of Disease study 2017'' by Chiang *et al*
Z Jin, J Zhao, L Sun
- e48** Correspondence on 'Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease'
J Chen, T Liu, J He, Y Liu
- e49** Response to: 'Correspondence on 'Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease'' by Chen *et al*
A Le Joncour, D Saadoun, Y Boulaftali
- e50** Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'
T Sun, J Ni
- e51** Response to: 'Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'' by Sun and Ni
B T P Gilbert, A Finckh, D Alpizar Rodriguez
- e52** Correction: 2022 American College of Rheumatology/ EULAR classification criteria for giant cell arteritis
- e53** Correction: Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis
- e54** Correction: Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis